It has generally been assumed that the skin contributes only minor amounts to the total uptake of solvent vapors, relative to the respiratory tract. Contrary to this assumption, the widely used glycol ether solvent, 2-butoxyethanol (BE), has been reported to be more effectively absorbed through the skin (75% of the total uptake) than through the lungs of humans (Johanson and Boman, 1991, Br. J. Ind. Med. 48,788). The possibility that the finger prick blood sampling technique used in the Johanson and Boman study was confounded by locally high concentrations of BE at the site of absorption was suggested using a previously developed PBPK model (Corley et al., 1994, Toxicol. Appl. Pharmacol 129,61). The current study was conducted to verify the PBPK analysis and to determine whether or not the skin was the major site for absorption of BE vapor by exposing one arm from each of six human volunteers to 50 ppm 13 C 2 -BE vapor for 2 hr. To evaluate the potential consequences of blood sampling techniques, samples were taken from both the unexposed arm (catheter; during and after exposure) and the exposed arm (finger prick; end of the exposure only) for analysis of both BE and its major metabolite, butoxyacetic acid (BAA). Butoxyacetic acid is responsible for the hemolysis observed in toxicity studies with laboratory animals. Humans, however, are significantly less sensitive to this effect The concentration of BE in the finger prick blood samples averaged 1500 times higher than the corresponding concentration in venous blood sampled from a catheter installed in the unexposed arm at the end of the exposure. Blood BAA levels were generally within a factor of 4 of each other for the two techniques and, therefore, was considered a better indicator of systemic absorption. Urine was collected for 24 hr and analyzed for the following metabolites found in rat metabolism studies: free and conjugated BE, BAA, ethylene glycol (EG), and glycol ic acid (GA), with only BAA detected in the human urine. More importantly, urinary BAA was found to be extensively conju-1 This work was presented in part at the 34th annual meeting of the Society of Toxicology, March 5-9, 1995, Baltimore, MD. This work was supported by the Ethylene Glycol Ethers Panel of the Chemical Manufacturers Association, Washington, DC. gated (~67%) with glutamine, confirming recent reports. These results, coupled with PBPK modeling of worst-case exposure scenarios (no clothing, 100% of the body was exposed), demonstrated that no more than 15-27% (low-to-high relative temperatures and humidities), not 75%, of the total uptake of BE could be attributed to the skin of humans during simulated 8-hr exposures to the ACGIH TLV concentration of 25 ppm. Even less of the total uptake was attributed to the skin during simulations of exercise with whole-body exposures (5-9%) or by more realistic exposures of only the arms and head (1-8%). As a result, humans are unlikely to reach hemolytic concentrations of the metabolite BAA in blood following vapor exposures to BE. o iw Sod«y of To A common practice in physiologically based pharmacokinetic (PBPK) modeling of vapor exposures is to assume that the skin does not contribute significantly to the total uptake of solvents compared to the respiratory tract. This practice has been based largely on the relative differences in surface area, barrier thickness, and blood perfusion rates which favor the absorption of solvent vapors via the lungs over that of the skin. The limited number of available studies with vapors have generally supported this assumption (Riihimaki and Pfaffli, 1978; McDougal et al., 1986 McDougal et al., , 1990 Jacobs and Phanprasit, 1993) . As a result, most PBPK models developed for volatile solvents have ignored this potential route of exposure.
It has generally been assumed that the skin contributes only minor amounts to the total uptake of solvent vapors, relative to the respiratory tract. Contrary to this assumption, the widely used glycol ether solvent, 2-butoxyethanol (BE), has been reported to be more effectively absorbed through the skin (75% of the total uptake) than through the lungs of humans (Johanson and Boman, 1991, Br. J. Ind. Med. 48,788) . The possibility that the finger prick blood sampling technique used in the Johanson and Boman study was confounded by locally high concentrations of BE at the site of absorption was suggested using a previously developed PBPK model (Corley et al., 1994, Toxicol. Appl. Pharmacol 129,61) . The current study was conducted to verify the PBPK analysis and to determine whether or not the skin was the major site for absorption of BE vapor by exposing one arm from each of six human volunteers to 50 ppm 13 C 2 -BE vapor for 2 hr. To evaluate the potential consequences of blood sampling techniques, samples were taken from both the unexposed arm (catheter; during and after exposure) and the exposed arm (finger prick; end of the exposure only) for analysis of both BE and its major metabolite, butoxyacetic acid (BAA). Butoxyacetic acid is responsible for the hemolysis observed in toxicity studies with laboratory animals. Humans, however, are significantly less sensitive to this effect The concentration of BE in the finger prick blood samples averaged 1500 times higher than the corresponding concentration in venous blood sampled from a catheter installed in the unexposed arm at the end of the exposure. Blood BAA levels were generally within a factor of 4 of each other for the two techniques and, therefore, was considered a better indicator of systemic absorption. Urine was collected for 24 hr and analyzed for the following metabolites found in rat metabolism studies: free and conjugated BE, BAA, ethylene glycol (EG), and glycol ic acid (GA), with only BAA detected in the human urine. More importantly, urinary BAA was found to be extensively conju-gated (~67%) with glutamine, confirming recent reports. These results, coupled with PBPK modeling of worst-case exposure scenarios (no clothing, 100% of the body was exposed), demonstrated that no more than 15-27% (low-to-high relative temperatures and humidities), not 75%, of the total uptake of BE could be attributed to the skin of humans during simulated 8-hr exposures to the ACGIH TLV concentration of 25 ppm. Even less of the total uptake was attributed to the skin during simulations of exercise with whole-body exposures (5-9%) or by more realistic exposures of only the arms and head (1-8%). As a result, humans are unlikely to reach hemolytic concentrations of the metabolite BAA in blood following vapor exposures to BE. o iw Sod«y of To A common practice in physiologically based pharmacokinetic (PBPK) modeling of vapor exposures is to assume that the skin does not contribute significantly to the total uptake of solvents compared to the respiratory tract. This practice has been based largely on the relative differences in surface area, barrier thickness, and blood perfusion rates which favor the absorption of solvent vapors via the lungs over that of the skin. The limited number of available studies with vapors have generally supported this assumption (Riihimaki and Pfaffli, 1978; McDougal et al., 1986 McDougal et al., , 1990 Jacobs and Phanprasit, 1993) . As a result, most PBPK models developed for volatile solvents have ignored this potential route of exposure.
Recently, however, a human pharmacokinetic study was published which contradicted this practice by concluding that dermal absorption of vapor was far more significant than respiratory uptake in humans exposed to 2-butoxyethanol (BE), an ethylene glycol ether used in a variety of hard surface cleaners (Johanson and Boman, 1991) . In their study, human volunteers were exposed mouth-only for 2 hr to 50 ppm BE, followed by 1 hr of no exposure, followed by 2 hr of skin-only exposure to 50 ppm BE (i.e., volunteers were exposed in a whole-body chamber while breathing fresh air through a face-mask). Using the areas under the curve for the concentration of BE in finger prick blood samples for the two exposures and the known clearances of BE for each of the volunteers determined in a previous kinetic study (Johanson et al., 1986) , Johanson and Boman calculated that approximately 75% of the total uptake of BE vapor was attributable to the skin. Corley et al. (1994) discussed the possibility that the finger prick blood sampling technique used by Johanson and Boman was confounded by the local absorption of BE and did not reflect the concentration of BE in "systemic blood," a necessary assumption for their classical, noncompartmental, pharmacokinetic analysis. By expanding their PBPK model for BE to include the dermal uptake of vapor, the data of Johanson and Boman were reanalyzed to explain how such an unusual conclusion regarding dermal absorption was reached. Simulations of their data were conducted assuming that the finger prick blood samples represented either (a) systemic arterial blood or (b) venous blood draining the skin compartment prior to systemic dilution, to estimate the skin permeability coefficient for BE under each condition. Additional simulations were conducted for another study from the same laboratory on the kinetics of BE following whole-body exposure to 20 ppm under exercise conditions (Johanson et al., 1986) . In each of these simulations, the assumption that the finger prick blood samples represented venous blood draining the skin compartment, and not systemic blood, provided the most consistent explanation of the available data.
While the question of dermal vapor absorption was particularly important for 2-butoxyethanol, there existed the potentially larger issue of incorrectly assuming that dermal uptake of certain solvent vapor is negligible compared to uptake in the lungs. Thus, a human dermal vapor kinetic study was conducted with BE to verify the previous simulations showing that the respiratory tract is far more important than the skin for the uptake of BE. The PBPK model was used to design the present study with particular attention to blood sampling methods and time of collection. Blood and urine samples were analyzed for the major metabolite, butoxyacetic acid (BAA), and its extent of conjugation by humans. BAA is primarily responsible for the hemolysis of red blood cells observed in laboratory animals (Ghanayem et al., 1987; Bartnik et al., 1987; Ghanayem, 1989) although humans are significantly less susceptible to this effect (Ghanayem, 1989; Udden, 1993; Ghanayem and Sullivan, 1993) . In addition, analyses for metabolites identified in studies with laboratory animals were included to improve the existing PBPK model.
METHODS
Experimental design. Six human volunteers were exposed, arm-only, to 50 ppm I3 C 2 -BE for 2 hr. Presumably due to the widespread use of cleaners containing BE, variable background levels of BE metabolites (up to 20-50 ppb) were detected in control human urine samples during methods development. As a result, the stable isotope, "Ci-BE, was used as the source of the vapor exposure to unequivocally relate the concentrations of BE and its metabolites to the controlled exposure and to achieve the very low detection limits (low ppb) in blood and urine that were necessary to conduct exposures of only one arm. Catheters were inserted into the antecubital vein of the opposite, unexposed arm as the primary source of systemic blood collection for the analysis of both BE and its major metabolite, BAA. Finger prick blood samples were taken from the exposed arm only at the end of the 2-hr exposure for analysis of both BE and BAA to compare with die blood samples obtained from the catheter. Urine samples were collected for metabolite analyses and to confirm a recent report that BAA is extensively conjugated with glutamine in humans (Rettenmeier et al., 1993) .
Chemicals. The test atmospheres were generated using "C 2 -butoxyethanol, labeled in the ethylene glycol backbone (CDN Isotopes, Vaudreuil, Quebec, Canada) with a purity of 99.54% as determined by capillary gas chromatography with thermal conductivity detection (GC-TCD). The metabolites, l3 C 2 -butoxyacetic acid with a purity of 94.2% (by GC-TCD) and 13 C 2 -ethylene glycol with a purity of 98.3% were synthesized by CDN Isotopes and The Dow Chemical Co., respectively. The internal standards, synthesized by The Dow Chemical Co., for quantitating BE, BAA and EG in blood and urine samples consisted of the deuterated analogues d7-BE, d7-BAA, and d4-EG, respectively. The identity of each of these compounds was confirmed by capillary gas chromatography electron impact mass spectrometry (GC/EI/MS). Authentic N-butoxyacetylglutamine (NBGL) was obtained from Dr. Albert Rettenmeier (University of Tubingen, Germany).
Subjects. Six healthy male volunteers, 20 to 45 years of age, participated in this study. Each subject received a complete physical examination and laboratory tests of hematopoietic, hepatic, and renal function prior to participating in the study. Medical histories and demographic data including sex, age, race, body weight, height, build, and smoking habits were recorded (Table 1 ). In addition, subjects were asked whether they had followed a normal diet in the previous 4 weeks, if they were taking medication regularly for a chronic condition, and whether they had donated blood in the previous 6 months. Subjects were excluded from a larger pool of volunteers if they had a history of significant cardiovascular, hepatic, CNS, renal, hematological, or gastrointestinal disease; skin problems, particularly on the arm to be used for exposure; alcoholism or drug abuse during the preceding year; abnormal diet during the 4 weeks preceding the study; personality disorders that would have precluded valid informed consent or compliance with protocol requirements; and if, through the completion of this study, they would have donated in excess of 900 ml of blood over the previous 20 weeks. Subjects were prohibited from receiving medication for 7 days preceding the study and from using alcohol or xanthine-containing beverages or foods for 24 hr prior to exposure and throughout the sample collection period Smoking was prohibited from 1 hr before to 4 hr after initiation of the exposure.
Subjects were housed at the L.A.B. Bio-Research Clinical Research Center from die evening prior to exposure until after the final blood and urine collection period (24 hr after initiation of the 2-hr exposure). The subjects fasted under supervision for at least 10 hr prior to exposure until approximately 0.5 hr postexposure. Standard meals were provided at 0.5 and 6 hr after exposure and at appropriate times thereafter. Water was withheld 2 hr prior to and during the exposure. Prior to exposure, each subject's arm was examined by a physician to determine that skin was intact and a venous catheter was installed in the unexposed arm.
This study was conducted in accordance with the clinical research guidelines established by the Medical Research Council of Canada, the Basic Principles defined in United States (21 CFR Part 312.120), and the principles enunciated in the Declaration of Helsinki (Hong Kong, 1989) . The protocol and informed consents were approved by the Bio-Research Institutional Review Board which is constituted and operated in accordance with the requirements for ethical considerations in research involving human subjects (Medical Research Council of Canada, Report No. 6, 1978 ; U.S. Code of Federal Regulations, 21 CFR Part 56).
Exposure conditions. Each subject exposed one arm to a target concentration of 50 ppm I3 C 2 -BE for 2 hr using a 400-liter Rochester-type stainless steel and glass inhalation chamber equipped with sealed entry ports for the arms. A thin rubber strap was suspended from the top of die chamber to support the subject's arm.
Test atmospheres were generated by pumping ' 3 C 2 -BE into a glass co- Subjects 1 -5 were Caucasian; subject 6 was black. 'The total body surface area (SA) was estimated using the formula of DuBois and DuBois (1916):
The SA for the whole arm was estimated to be 9% of the total body surface area (Boyarsky and Smith, 1957; Raisz and Scheer, 1959) . The SA for the exposed arm was calculated from total arm -unexposed part (circumference X length).
lumn filled with glass beads where heated air was passed to vaporize the test material according to Miller et al. (1980) . The concentration of I3 C 2 -BE was monitored continuously using a Miran 1A infrared analyzer (Foxboro Co., Foxboro, MA). At 2-min intervals, the concentration was recorded and time-weighted average concentrations were calculated for each subject since each exposure session could accommodate three subjects at a time with each subject inserting their arm at staggered intervals to allow for the collection of blood samples.
Blood sampling and analysis.
Peripheral venous blood samples were obtained via the antecubital vein catheter in the nonexposed arm before exposure and at 10, 20, 30, 40, 60 min and 1.5, 2, 2.25, 2.5, 3, 3.5, 4, 8, 12, 16 , and 24 hr after the initiation of the 2-hr exposure. The samples were drawn into heparinized Vacutainers, divided into two polypropylene tubes, and frozen at -15°C until the last sample was collected. Immediately after exposure, the hands used for finger prick sampling were immersed twice in fresh, lukewarm water for approximately 30 sec to wash the surface of the skin and produce capillary vasodilation according to the procedure used by Johanson and Boman (1991) . The finger prick blood samples were then collected into two 700-^1 Microtainers containing heparin, transferred to polypropylene tubes, and frozen at -15°C until the last sample was collected. The exposed arm was then rinsed under running water and cleansed with a mild soap. All samples were then shipped on dry ice to The Dow Chemical Co. where they were stored frozen (-80°C) until analyzed (within 2 weeks). Analyses of 13 C 2 -BE and I3 C 2 -BAA, as their respective pentafluorobenzoyl and pentafluorobenzyl derivatives, were conducted by capillary gas chromatography with negative chemical ionization-mass spectrometry according to the method of Bormett et al. (1995) . Detection limits for I3 C 2 -BE and I3 C 2 -BAA in blood were 1.5 ng/g for each material or 0.013 and 0.011 fiM, respectively.
Urine collection and analysis.
A urine sample was obtained from each subject before exposure and at 0-to 12-and 12-to 24-hr intervals following initiation of exposure. The urine was refrigerated (~4°C) until the end of each collection interval, the volume and pH of each interval were recorded, and two aliquots (~10 ml each) were taken and frozen from each interval for analysis of metabolites. Analyses of free I3 C 2 -BE and 13 C 2 -EG in the urine as their respective pentafluorobenzoyl derivatives and free I3 C 2 -BAA as a pentafluorobenzyl derivative were conducted by capillary gas chromatography with negative chemical ionization-mass spectrometry according to the method of Markham et al. (1995) . Total (free and conjugated) 13 C 2 -BE, I3 C 2 -BAA, and I3 C 2 -EG were also determined after acid hydrolysis. Detection limits for free and total I3 C 2 -BE, I3 C 2 -BAA, and I3 C 2 -EG in urine were 35.8 ng/g (0.30 /IM), 84.0 ng/g (0.64 /XM), and 25.6 ng/g (0.41 UM), respectively.
The analysis for glycolic acid (GA), a major metabolite of EG, in urine was conducted after the original protocol was completed and was, therefore, based on I2 C-GA external standard quantitation. Extraction and analyses for the pentafluorobenzoyl and pentafluorobenzyl derivatives of alcohol and acid functional groups of GA, respectively, were similar to the method used for analysis of BE and BAA by capillary gas chromatography with negative chemical ionization-mass spectrometry.
To confirm the identity of the NBGL conjugate, urine samples were filtered (0.2 fim Anotop 10; Alltech Assoc., Inc., Deerfield, IL) and analyzed by gradient reversed-phase HPLC with positive electrospray ionization/ mass spectrometry (+ESI/MS) according to Markham et al. (1995) . The detection limit for the NBGL conjugate was 200 ng/g (0.73 /JM).
Fortified control blood and urine shipment samples.
To ensure the integrity of the blood and urine samples shipped from L.A.B. Bio-Research to The Dow Chemical Co. for analysis of metabolites, replicate fortified controls were prepared from each subject's blood and urine collected prior to exposure. The blood samples were spiked with known amounts of BE and BAA and the urine samples were spiked with BE, BAA, and EG. All fortified samples were prepared, treated, and shipped along with the samples obtained following exposure to I3 C 2 -BE.
Clinical pathology.
Blood samples for hematology were collected just prior to exposure, at the end of exposure, and at approximately 24 hr after initiation of exposure (see Table 2 ). Samples for serum chemistry were collected approximately 24 hr after initiation of exposure (Table 2) . Approximately 12 hr after initiation of exposure, a blood sample was taken for creatinine clearance determination.
A sample of urine was taken approximately 24 hr after initiation of the exposure for urinalysis (see Table 2 ). When the 24-hr collection interval was completed and samples were taken for analysis of BE and metabolites, all remaining urine was pooled for each subject and one aliquot was taken for creatinine clearance determinations.
Calculations.
The concentrations of BE and BAA in blood samples collected from the exposed arm by finger prick at the end of the exposure were compared to samples collected from the unexposed arm via catheter using a two-way analysis of variance (SAS for microcomputers. Version 6.04, SAS Institute, Cary, NC). The areas under the curve for both BE and BAA were calculated by the trapezoidal rule from 0 to 24 hr (AUQ,.},) and extrapolated to infinity (AUC) by addition of the quantity equal to the last measurable concentration divided by the elimination rate constant (*" d ).
The apparent first-order elimination rate constant (K^) was calculated from a log-linear plot of the last three (or more) nonzero concentrations in the blood concentration vs time curve. The terminal phase blood half-life was obtained by dividing 0.693 by the elimination rate constant (K el ). The maximum measured blood concentration of BE and BAA (C^ and the time of the maximum value (ij were also determined. The permeability coefficient (ip) for the dermal uptake of BE was determined by fitting the model to the concentration of BE and BAA in blood from this study and the concentration of BE in finger prick blood from the Johanson and Boman (1991) study using the PB-PK model of Corley et al. (1994) .
RESULTS
Exposure conditions. The concentration of 13 C 2 -BE vapor, determined by fixed-wavelength IR analysis, for each of the subjects averaged 50.2 ppm with an overall nominal concentration (total amount of material used divided by the total volume of air) of 51.9 ppm (Table 3 ). The chamber temperatures (23-25°C) were similar to the "normal" temperature used by Johanson and Boman (1991) (mean of 22.6°C) while the relative humidity (55-58%) was between the "normal" (mean of 29%) and "raised" humidities (mean of 71%).
Clinical pathology and health status. The total blood volume collected in this study did not exceed 136 ml, except for subject 3, whose prestudy hematological evaluation was repeated, bringing his total blood volume collected to 141 ml. No significant deviations were observed in the postexposure hematological, serum chemistry, or urinalysis data even with an emphasis on markers for hemolysis (data not shown). Subjects were monitored throughout the 24 hr of confinement after the initiation of the exposure with no adverse events reported.
BE toxicokinetics. BE was not detected in blood samples from the unexposed arm until 30 min into the exposure * No meaningful K^ was determined for subjects 1,4,5, and 6. Therefore, AUC and apparent elimination phase half-lives could not be calculated for BE in these individuals.
* Represents the mean ± SD of the individual subject ratios of finger prick:catheter blood concentrations (rather than a ratio of the means provided in this table). (subjects 2 and 4, only) (Fig. la) . By 1.5 hr, BE was detectable in all six subjects. An apparent steady state was reached for the concentration of BE in systemic blood between 1.5 and 2 hr (Fig. la) . Interestingly, the concentration of BE in blood was nearly twofold higher in the first blood sample taken 15 min after the exposure ceased than it was at the end of the exposure in all but one volunteer (subject 2; Fig.  la) . BE was rapidly cleared from the blood with an apparent elimination half-life of 0.66 hr based upon two of the six subjects data (Table 3 ). Due to the rapid loss of BE from venous blood, no meaningful half-lives or AUC's could be calculated for the other four subjects.
BAA toxicokinetics. As with BE, BAA was not detected in blood samples from the unexposed arm until 30 min into the exposure (subjects 2 and 4-6) with amounts detected in all six subjects by 1 hr (Fig. lb) FIG . 2. Proposed metabolic scheme for 2-butoxyethanol in rats and humans. BAA-Glu and BAA-Gly are the glutamine and glycine conjugates of BAA, respectively. According to Rettenmeier et al. (1993) , the glutamine conjugate represents approximately 90% of the amino acid conjugates of BAA in humans.
ceeded those of BE at all time points. Peak blood concentrations of 0.44-0.92 fiM were reached 3-4 hr after the start of the 2-hr exposures (Table 3) . BAA was less rapidly cleared from the blood than BE with an apparent elimination half-life of 3.27 ± 0.72 hr.
Comparison of blood sampling techniques. For the parent compound, BE, the ratio of the finger prick blood samples taken at the end of the 2-hr exposure to the corresponding blood sample taken from the catheter installed in the unexposed arm, averaged nearly 1500:1 (Table 3) , indicating a considerable influence by local absorption for the finger prick blood samples. Moreover, the concentrations of BE in the finger prick blood samples were, on average, 37 times higher than the concentrations of BAA. This is the opposite of the catheter blood sample, in which the concentrations of BE were approximately one-tenth the concentration of BAA at the end of the exposure. The concentrations of BAA in both blood samples were much more consistent than that of BE and were, on average, within a factor of four of each other.
Urinary metabolite profiles.
No free BE was detected in any urine sample (see Fig. 2 ). Following hydrolysis to cleave acid-labile conjugates, BE was detectable in only two 0-to 12-hr urine samples at concentrations of 43 (subject 3) and 48 ng/g (subject 6). These concentrations were only slightly higher than the detection limit of 35.8 ng/g BE in urine (data not shown).
No free or acid-labile conjugates of ethylene glycol were detected in any urine sample [25.6 ng/g (free) and 16.7 ng/g (acid-hydrolyzed) detection limits]. Glycolic acid, a major metabolite of ethylene glycol, also was not detectable above a highly variable background concentration of 2.5 to 13 /xg/g. Corresponding to the relatively short half-life in blood, the major metabolite, BAA, was eliminated primarily in the urine during the first 12-hr collection interval (Table 4) . Consistent with the observations of Rettenmeier et al. (1993) , approximately two-thirds of the total amount of BAA excreted in the urine was in the form of an acid-labile conjugate, NBGL. The identity of the NBGL conjugate was confirmed by reversed-phased HPLC with positive electrospray ionization/mass spectrometry (+ESI/MS).
Skin permeability coefficient. Using the data from this study and the Johanson and Boman (1991) study, the best estimates of k p , were 2 or 4 cm/hr for normal (23°C, 29% RH) and elevated (33°C, 71% RH) temperatures and humidities and were unchanged from those determined previously (Corley et al., 1994) . Since there were no statistically identified differences between the normal and elevated temperature/humidity data of Johanson and Boman (1991) , an average permeability coefficient (fcp = 3 cm/hr) was used for general simulations in Figs. 3 and 4.
DISCUSSION
In a previous human vapor exposure study, a unique design was used to evaluate the relative contributions of the skin and the lungs to the total uptake of BE (Johanson and Boman, 1991) . This required a significant effort to control for possible artifacts associated with the operation of respirators, chambers, and blood sampling methods, all while collecting physiological data on heart and ventilation rates. In the current study, arm-only exposures were used to simplify the design and minimize potential artifacts that could occur with the use of respirators and whole-body exposures.
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CLabeled test material was necessary to achieve the very low detection limits that were required to conduct an arm-only vapor exposure study and to unequivocally identify BE and its metabolites in blood and urine resulting from this controlled exposure.
The elimination kinetics of BE and BAA in this study were consistent with previous studies and appeared to be independent of the type of exposure. The half-lives for the elimination of BE and BAA in this study average 0.66 hr (range: 0.6-0.72 hr in the two subjects for which a meaningful half-life could be determined) and 3.27 hr (range: 2.35-4.38 hr), respectively. In the Johanson and Boman study, the elimination half-life of BE averaged 0.53-0.6 hr following dermal absorption. Following whole-body exposures under exercise conditions, the elimination halflives for BE and BAA were 0.66 and 4 hr, respectively (Johanson et al., 1986; Johanson and Johnsson, 1991) . For dermal exposures to neat liquids, the half-lives for the elimination of BE and BAA were 1.3 and 3.1 hr, respectively (Johanson et al., 1988) .
The kinetics of BE in the blood of one volunteer during Note. Urine samples were collected in two 12-hr intervals for each subject, sampled for analysis of free and total (acid hydrolyzable) BE, BAA, ethylene glycol, and glycolic acid, then combined for analysis of creatinine. Only BAA (free and conjugated) was detected in these samples. Ranges for individual subject values are given in parentheses. Experimental data (means ± SD) and simulations (lines) for the concentrations of (a) BE and (b) BAA in the blood of humans exposed arm-only to 50 ppm I3 C-BE for 2 hr. Simulations were conducted assuming that only one metabolic pathway (via the formation of BAA) operates in humans In (a), the concentration of BE in blood was simulated using "normal" physiological parameters throughout the simulation and by increasing the blood flow to the skin for 5 min postexposure to simulate movement following 2 hr of restraint. and immediately postexposure appeared different than the other volunteers (Subject 2, Fig. 1 ). Peak blood concentrations of BE occured prior to the end of the exposure and no postexposure increases in BE concentrations were observed. The reasons for this difference are unknown and may reflect either experimental variability or physiological differences. However, the clearance of BE from this subject was similar Comparison between PB-PK simulations (lines) and the concentrations (symbols) of (a) BE and (b) BAA in the blood of humans exposed to 20 ppm BE for 2 hr while exercising (50 W) on a bicycle ergonometer (Johanson et al, 1986; Johanson and Johnsson, 1991) . Simulations were conducted using the model structure of Corley et al. (1994) (dotted lines: V mi 2C = 5 mg/hr/kg) and by assuming that only one metabolic pathway (via the formation of BAA) operates in humans (solid line: V mu 2C = 0).
to that of other subjects and had a half-life of BE in blood similar to values reported in the literature.
Data from this study were used to validate the analysis of Corley et al. (1994) indicating that the finger prick blood sampling technique used by Johanson and Boman (1991) resulted in an incorrect conclusion that dermal uptake of BE is quantitatively more important than respiratory uptake in humans exposed to BE vapor. Their conclusion was based on the assumption that the finger prick blood samples represented systemic arterial blood concentrations of BE. In the current study we verified that, when analyzing only for the parent chemical, finger prick blood samples most likely represented both systemic concentrations and local concentrations of the compound in venous blood draining the skin. A comparison of these two assumptions of the source of the finger prick blood sample is depicted in Fig. 4 of Corley (1996) where a significant overestimate of the uptake of BE vapor through human skin occurred when finger prick blood samples were assumed to represent systemic blood.
In addition, the concentrations of BE and BAA in the finger prick blood samples taken from the exposed arms in this study were not comparable to the concentrations seen in blood samples taken from the catheter inserted in the antecubital vein of the opposite, unexposed arm (Table 3) . In this case, the concentrations of BE averaged nearly 1500-fold higher in the finger prick blood samples versus the corresponding samples taken from the unexposed arm at the end of the exposure. Differences in blood concentrations between exposed and unexposed arms have also been documented for topical applications of liquid formulations. For example, concentrations of MN-diethyl-m-toluamide (DEET) in blood taken from the exposed arm were considered to be indicative of dermally absorbed DEET plus circulating DEET while the concentrations in blood taken from the unexposed arm were considered to be indicative of only systemically circulating DEET (Selim et al, 1995) .
For the major metabolite, BAA, the concentrations were within a factor of four of each other using the two blood sampling techniques (Table 3 ). The reason for the higher concentration of BAA in finger prick blood samples (statistically significant) than in blood obtained from the catheter is unknown. This difference could reflect any combination of local metabolism of BE to BAA in the skin, or a slight preference of human skin versus blood to accumulate BAA (due to differences in solubility or protein binding), or to the fact that the finger prick blood samples were inevitably taken a few minutes after the catheter samples while the concentration of BAA in blood was rapidly increasing because of the time needed to wash and prepare the exposed area for sampling. Regardless, this difference in BAA concentration was slight relative to the 1500-fold difference between the two techniques for the parent compound.
Lastly, the ratios of the concentration of BE to BAA in finger prick blood samples taken at the end of the exposure were the opposite (BE > BAA) of the ratios from the unexposed arm (BAA > BE), the latter of which are more consistent with the pharmacokinetics of BE and BAA (Table 3) . Had Johanson and Boman included BAA in their analyses, it is likely that this discrepancy would have been uncovered. Taken together, these data demonstrate that finger prick blood sampling is an inappropriate technique for the analysis of parent compounds following dermal exposures under resting conditions unless the source of the blood can be factored into the analysis. This can be readily accomplished with a PBPK model. Thus, the alternative assumption that finger prick blood samples represented venous blood draining the skin was used to calculate the permeability coefficient for the uptake of BE vapor through the skin from the data of Johanson and Boman. As described by Corley et al. (1994) , this assumption, as verified in this study, provided the most consistent simulation of all of the available human data sets.
The confirmation of a glutamine conjugate of the major metabolite, BAA, in human urine (Table 4) further demonstrates the difficulties in extrapolating toxicity data developed in rats to humans without a metabolic and kinetic bridge between the species. Biochemical constants for the formation of the NBGL conjugate from BAA and its elimination in urine would have to be added and verified in the PBPK model if a complete description of the fate of the hemolytic metabolite, BAA, in humans were desired. Preliminary analyses of the blood samples from this arm-only study for the NBGL conjugate failed to find significant concentrations (compared with BAA concentrations; data not shown) indicating that NBGL is rapidly cleared after its formation (presumably in the liver) via glomerular filtration and not reabsorbed intact. Incorporation of this pathway may account from some of the previous overpredictions of the amounts of BAA excreted in the urine (Corley et al., 1994) . However, current descriptions of total BAA (free plus protein-bound) in the blood of rats and humans, which is relevant for hemolysis, are still adequate and can be used in cross-species, dose-route, and high-to-low dose extrapolations.
Since no free or conjugated BE, ethylene glycol (free or conjugated), or glycolic acid were found in the urine of humans in the present study, these metabolic pathways, which together account for approximately 25-30% of the metabolites in rats (see Fig. 2 for the proposed metabolic scheme) were eliminated from the human PBPK model developed previously (Corley et al., 1994) . Simulations of the data from the present arm-only study, along with the previous human, kinetic study of Johanson et al. (1986) and Johanson and Johnsson (1991) , are shown in Figs. 3 and 4 , respectively. Although the model predicted a higher area under the curve and C^ for BE in blood than was observed in this arm-only study, the observed data and simulations were within a factor of two of each other. More importantly for health risk assessments based on hemolysis, the simulated concentrations of BAA in blood were in very close agreement with the data. Adjustments to the permeability coefficient to improve the fit of the arm-only exposure data would have resulted in a correspondingly decreased ability to fit the BAA data from the arm-only study as well as the other two human studies, which were well-described. Thus, the choice of the skin permeability coefficient represented a balance between the different studies to achieve an overall description of the available data.
The increases observed in the concentration of BE in blood immediately after the exposures ceased in five of the six subjects were unexpected (Fig. la) . However, when consideration was given to the fact that the subjects were partially immobilized during the exposure and were allowed to move freely about only after the exposure ceased and finger prick blood samples were obtained, it is reasonable to expect a change in the local blood flow to the exposed arm. When the PBPK model was adjusted by increasing the blood flow to the skin for only 5 min postexposure (fourfold increase), this change in the concentration of BE in blood was duplicated by the model (Fig. 3a) . Alternatively, washing the arm after the exposure ceased may have altered the permeability of the skin and thus momentarily enhanced the absorption of any residual BE on the surface of the skin into circulation. However, in this vapor exposure, the amount of residual BE on the surface should be minimal and the postexposure increases can be explained by locally altered blood flow to the skin.
Using the existing PBPK model for BE and BAA (Corley et al., 1994) and deleting the secondary pathways for the metabolism of BE via MFO (ethylene glycol pathway) and conjugation (glucuronidation or sulfation), estimates of the relative contribution of the skin to the total uptake of BE by humans exposed to the ACG1H TLV concentration of 25 ppm for 8 hr were calculated for resting and exercise conditions (Table 5) . Dermal exposures were simulated assuming both worst-case conditions where no clothing is worn (100% of the total body surface area was fully exposed) and more realistic conditions where only 25% of the total body surface area, such as when parts of both arms and the head, are exposed. Under worst-case resting conditions, where respiratory rates are at their lowest and no clothing is worn, the skin can account for no more than 15-27% (normal-elevated temperatures and humidities as used by Johanson and Boman, 1991) of the total uptake of BE vapor, not 75% as discussed previously. With more realistic exposures (25% of the surface area), the skin accounted for 4.4-8.4% of the total uptake using the lower respiratory rates of resting conditions. Under simulations of exercise (50 W) with elevated respiratory rates and cardiac output, dermal uptake accounted for 1.2-2.3% and 4.6-8.7% of the total uptake assuming either 25 or 100% of the body surface area was exposed, respectively. With the absorption of BE driven pri- c. Simulations of a 70-kg human exposed whole-body to the ACGIH TLV concentration of 25 ppm continuously for 8 hr under resting or exercise (50 W) conditions with the PBPK model of Corley et al. (1994) using the modifications described in the text. Dermal uptake was assumed to occur under either worst-case conditions where no clothing was wom (100% of the total body surface was fully exposed to BE vapor for the entire 8 hr) or more realistic exposures where most of both arms and the head region were exposed (25% of the total surface area). A series of skin permeability coefficients were used to simulate the normal (>tp = 2 cm/hr; 23°C, 29% RH) and elevated (/kp = 4 cm/hr, 33°C, 71% RH) relative temperatures and humidities used by Johanson and Boman (1991) . The average permability coefficient (Jtp = 3 cm/hr) was also included, since it was used for general simulations as described in the text. Peak blood concentrations (C^) of BAA for each simulation were calculated for comparison to the in vitro hemolytic no effect level of 2000 fiM for normal humans and humans with potential susceptibility (Udden and Patton, 1993; Udden, 1993). marily by the respiratory tract, the total uptake estimates and peak blood concentrations for BAA for the different skin permeabilities were not significantly different from each other within each set of simulations for resting and for exercise conditions. Peak blood concentrations of BAA were compared to the in vitro no effect level of 2 ITIM in 4-hr incubations of BAA with blood from normal humans and humans with potential susceptibility to hemolysis (Udden and Patton, 1993; Udden, 1993) . The in vitro NOEL was 32-to 42-fold higher than peak blood concentrations predicted for resting physiology and approximately 10-to 11-fold higher than peak blood concentrations predicted under exercise conditions for an 8-hr continuous exposure to 25 ppm BE (Table 5 ). More recent in vitro studies with human blood suggest that prehemolytic changes (increased osmotic fragility) are not reached until concentrations are well above 5 mM in 4-hr incubations (Udden, personal communication), a concentration that is unlikely to be achieved except when large quantities of BE are intentionally ingested.
In conclusion, data from this study confirmed our hypothesis that blood sampling techniques can have a significant impact on pharmacokinetic analyses and interpretation of controlled human exposure studies, especially when the dermal route of exposure is used and only the parent chemical is analyzed. Consistent with other solvents, the respiratory tract represents the most significant contributor to the total uptake of BE vapor. As a result, the use of appropriate respiratory protection will effectively reduce the overall internal dose of BE in situations where vapor exposures are expected. Furthermore, the use of protective clothing will further reduce the uptake of BE vapor by the skin and minimize exposure to liquids containing BE, the other potentially significant route for human exposures.
